ArticleClinical pharmacology and therapeutics2020
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Article in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.Clinical and translational science · 2021Pooled it
- Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients.Journal of the Chinese Medical Association : JCMA · 2021Pooled it
- A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment.Scientific reports · 2020Pooled it
- Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.Molecules (Basel, Switzerland) · 2020Pooled it
- Correction to "Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing".Clinical pharmacology and therapeutics · 2025Article
- Article
- A network biology approach to identify crucial host targets for COVID-19.Methods (San Diego, Calif.) · 2022Article
- Modelling upper respiratory viral load dynamics of SARS-CoV-2.BMC medicine · 2022Article
- Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2.Frontiers in pharmacology · 2022Article
- Article
- A review of mathematical model-based scenario analysis and interventions for COVID-19.Computer methods and programs in biomedicine · 2021Review
- Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients.Pharmaceutics · 2021Article
- Brief review on repurposed drugs and vaccines for possible treatment of COVID-19.European journal of pharmacology · 2021Review
- Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.Microbial drug resistance (Larchmont, N.Y.) · 2021Review
- Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.Journal of medical virology · 2021Article
- Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.Journal of clinical pharmacy and therapeutics · 2021Review
- Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.Xenobiotica; the fate of foreign compounds in biological systems · 2021Review
- Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus disease of 2019 (COVID-19) treatment. The optimal dosing of HCQ is unknown. Our goal was to integrate historic and emerging pharmacological and toxicity data to understand safe and efficacious HCQ dosing strategies for COVID-19 treatment. The data sources included were (i) longitudinal clinical, pharmacokinetic (PK), and virologic data from patients with severe acute respiratory syndrome-2 (SARS-CoV-2) infection who received HCQ with or without azithromycin (n = 116), (ii) in vitro viral replication data and SARS-CoV-2 viral load inhibition by HCQ, (iii) a population PK model of HCQ, and (iv) a model relating chloroquine PKs to corrected QT (QTc) prolongation. A mechanistic PK/virologic/QTc model for HCQ was developed and externally validated to predict SARS-CoV-2 rate of viral decline and QTc prolongation. SARS-CoV-2 viral decline was associated with HCQ PKs (P < 0.001). The extrapolated patient half-maximal effective concentration (EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.